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Blocking distinct interactions 
between Glioblastoma cells and 
their tissue microenvironment: A 
novel multi-targeted therapeutic 
approach
Melanie Mettang1,2, Viola Meyer-Pannwitt1,3,4, Georg Karpel-Massler5, Shaoxia Zhou6, 
Neil O. Carragher7, Karl Josef Föhr  8, Bernd Baumann2, Lisa Nonnenmacher1, Stefanie 
Enzenmüller1, Meike Dahlhaus1, Markus D. Siegelin9, Sebastien Stroh1,10, Daniel Mertens3,4, 
Pamela Fischer-Posovszky1, E. Marion Schneider6, Marc-Eric Halatsch5, Klaus-Michael 
Debatin1 & Mike-Andrew Westhoff  1
Due to the highly invasive nature of Glioblastoma (GB), complete surgical resection is not feasible, while 
motile tumour cells are often associated with several specific brain structures that enhance treatment-
resistance. Here, we investigate the therapeutic potential of Disulfiram and Carbenoxolone, that inhibit 
two distinct interactions between GB and the brain tissue microenvironment: stress-induced cell-matrix 
adhesion and gap junction mediated cell-cell communication, respectively. Increase in cell numbers of 
tumour-initiating cells, which are cultured in suspension as cell clusters, and adherent differentiated 
cells can be blocked to a similar extent by Carbenoxolone, as both cell populations form gap junctions, 
but the adherent differentiated cells are much more sensitive to Disulfiram treatment, which – via 
modulation of NF-κB signalling – interferes with cell-substrate adhesion. Interestingly, inducing 
adhesion in tumour-initiating cells without differentiating them does not sensitize for Disulfiram. 
Importantly, combining Disulfiram, Carbenoxolone and the standard chemotherapeutic drug 
Temozolomide reduces tumour size in an orthotopic mouse model. Isolating GB cells from their direct 
environment within the brain represents an important addition to current therapeutic approaches. The 
blockage of cellular interactions via the clinically relevant substances Disulfiram and Carbenoxolone, 
has distinct effects on different cell populations within a tumour, potentially reducing motility and/or 
resistance to apoptosis.
Glioblastoma (GB), formerly Glioblastoma multiforme, is the most common cancer of the central nervous 
system with poor prognosis exemplified by patient survival of about one year after diagnosis1. Despite inten-
sive treatment involving tumour resection, radiation and chemotherapeutic treatment with Temozolomide 
(TMZ), GB inevitably recurs2. GB is a highly aggressive malignancy with rather unique features: while it only 
rarely metastasizes outside the neuraxis3, it is almost invariably found to be highly invasive upon presentation4. 
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It is still debated whether GB should be viewed as a tumour within the brain or a systemic whole brain disease. 
The latter view had been particularly popular among early radiation oncologists5 and is currently gaining favour 
once more6. In extreme cases, GB can be lethal in the complete absence of tumour bulk4. The unfocused nature 
of this disease makes localized treatment, e.g. maximal safe surgery, particularly ineffective7. After excision of the 
tumour bulk, recurrence manifests within 2–3 cm of the resection cavity in more than 95% of cases4. The invading 
GB cells often associate with distinct anatomic structures, e.g. myelinated axons, basement membranes of blood 
vessels, other basement membrane-like structures, and the so-called “secondary structures of Scherer”8. These 
structures are known to confer increased resistance to apoptosis9,10 by inducing various pro-survival signalling 
cascades – a phenomenon we have previously referred to as AMAR, or adhesion-mediated apoptosis resistance11. 
Previous targeted therapies blocking individual adhesion receptors such as cilengitide (inhibitor of αvβ3 and 
αvβ5 integrins) have had limited efficacy in GB clinical trials12. The poor efficacy of targeted adhesion blocking 
therapies may be limited in part by redundancy in multiple adhesion receptor mediated signalling events, which 
confer AMAR across the disseminated GB microenvironment of the brain. Therefore, a multi-targeted approach 
of blocking adhesion signalling in GB should minimize the interaction of tumour cells with their surroundings, 
reduce invasion and re-sensitize cancer cells for apoptosis. To test this hypothesis, we selected two forms of cellu-
lar interaction which have been shown to contribute to GB biology – cell-matrix interactions and gap junctions.
Cell-matrix interactions are usually formed via integrin engagement that tethers the cell to its surroundings 
and activates complex intracellular signalling cascades11. We recently showed that invasive GB cells are asso-
ciated with fibronectin that is secreted and processed by the tumour cells via plasminogen and matrix metal-
lopeptidases13. Importantly, the creation of this new extracellular matrix (ECM)-based microenvironment was 
initiated upon a stress response resulting from the reduction of cell-cell interactions, which triggered NF-κB 
activation13. Blocking NF-κB activation via the nonspecific, but well-tolerated, inhibitor Disulfiram (DIS) reduces 
both tumour bulk and cellular invasion in an orthotopic mouse model13. This is also in line with previous data 
that suggest that Disulfiram-mediated inhibition of NF-κB sensitizes colorectal cancer cells for cell death14.
In contrast, gap junctions are formed between adjacent cells. They have been described to form transiently 
during invasion between GB cells and astrocytes as well as part of long-distance multicellular network struc-
tures15,16. Our own data, using the glycyrrhetinic acid-derivative Carbenoxolone (CBX) for the inhibition of gap 
junctions, also suggest that stable gap junctions contribute to the close cell-cell interaction associated with the 
tumour bulk, and that these structures clearly contribute to apoptosis resistance17. Therefore, we postulated that 
inhibition of cell-fibronectin interaction should mainly affect invasive/stressed cells, while blocking gap junctions 
should influence both invasive cells and tumour bulk - the latter more strongly however, as gap junctions are more 
stable in that context.
To mimic the intratumoral heterogeneity, i.e. the existence of competing and supporting subpopulations of 
tumour cells that adds to the complexity of the disease18 in an experimental system, we used two genetically iden-
tical cell populations with different forms of dominant cellular interactions. GB stem-cell like cells, also referred 
to as tumour-initiating cells (TiCs), are cultured as free-floating clusters, i.e. communicating mainly via stable 
gap junctions. Within the tumour, they make up only a small fraction of total cells, but are responsible for the 
overall phenotype and are thought to be resistant to radio- and chemotherapy and thus lead to persistent tumour 
regrowth19,20. The main tumour bulk consists of differentiated GB cells (Difs), which experimentally are cultured 
adherently, forming cell-matrix contacts13. Importantly, functional differences between TiCs and Difs are not only 
due to different forms of cellular contacts, but also due to their alternative states of differentiation, even though 
they are derived from the same GB patient, i.e. of identical genetic origin.
In this work, we evaluated the potential of a complex combination therapy that is primarily aimed to isolate 
GB cells within the brain from their microenvironment. Specifically, we were able to show that the two major 
forms of cellular interactions, cell matrix-interaction and gap junctions, were blocked in primary GB cells via 
treatment with DIS and CBX. Importantly the two compounds did not antagonize each other when given in com-
bination and when combined with chemotherapy, such as TMZ in an orthotopic mouse model.
Methods
Primary tumour material. After patients’ informed consent, GB-TiC spheres were grown from surgical 
specimens and cultured as previously described21. Briefly, TiCs were cultured in supplemented DMEM/F-12 
(HAM) medium (Invitrogen, Darmstadt, Germany). Adherent TiCs were cultured in non-tissue culture flasks 
(Sarstedt, Nümbrecht, Germany) pre-treated with collagen type I (BD Biosciences, Bedford, MA, USA) for 1 hour 
at 37 °C. Dif cells were grown in supplemented DMEM medium (Invitrogen).
Changes in cell number. Cells were counted using CASY1 DT (OMNI Life Science, Bremen, Germany), as 
previously described13.
Apoptosis measurement. Apoptosis was determined by fluorescence-activated cell-sorting (FACScan, 
Becton Dickinson, Heidelberg, Germany) analysis, using DNA fragmentation of propidium iodide (PI)-stained 
nuclei as a surrogate readout13. Shown is the specific DNA fragmentation, calculated as follows: 100× (experi-
mental DNA fragmentation (%) - spontaneous DNA fragmentation (%))/(100%-spontaneous fragmentation (%)) 
and analysed by two-way ANOVA followed by Bonferroni’s post-test.
Inhibitors and drugs. Tetraethylthiuram disulfide (DIS), Temozolomide (TMZ) and Carbenoxolone diso-
dium (CBX) were obtained from Sigma-Aldrich (Steinheim, Germany) and dissolved in DMSO (DIS and TMZ) 
or water (CBX). For in vivo experiments CBX was replaced by INI-0602 (Wako Pure Chemical Ind., Ltd., Japan).
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Time-lapse photography. Time-lapse photography was performed by taking a picture of the cells every 
ten minutes over a time frame of at least 48 hours under a CK40 microscope with a CAMEDIA C-4040ZOOM 
digital camera (Olympus, Hamburg, Germany). The relative speed of cells was quantified using ImageJ software 
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 
1997–2011).
Orthotopic mouse model. 1.0 × 105 G35-TiCs were transplanted into NOD.Cg-PrkdcscidII2rgtm1WjI/
SzJ mouse brains as previously described22 and in accordance with relevant guidelines and regulations. Tissue 
samples were stained with haematoxylin and for expression of vimentin (Abcam plc), as previously described13.
Comparative gene expression profiles of GB and healthy brain. Gene expression data were analysed 
via the Oncomine Software (www.oncomine.com, May 2016, Thermo Fisher Scientific, Ann Arbor, MI), which 
is available to the public23. Reporter details: Fig. 1a – NFKB1 - Reporter 209239_at (TCGA Brain), Fig. 1b – Rela 
- Reporter 201783_s_at (TCGA Brain), Fig. 1c – GJA1 - Reporter 201667_at (TCGA Brain), Fig. 1d – GJA3 - 
Reporter 208590_x_at (TCGA Brain), Fig. 1e – GJA4 - Reporter 40687_at (TCGA Brain) and Fig. 1f – GJA10 
- Reporter 1553044_at (Sun Brain).
GB patient survival data. Overall and progression free survival data were obtained from the R2: Genomics 
Analysis and Visualization Platform (r2.amc.nl), which is available to the public. The raw data was retrieved from 
the GB TCGA data set (TCGA–540–MAS5.0–u133a; R2 internal identifier: ps_avgpres_broadGB540_u133a) and 
used for the analysis within R2. The expression cut-off for NFKB1 (209239_at) was 50.7, and for GJA1 (201667_
at) 160.1 (event free survival and 1219.3 (overall survival), subset: WITH_SURV.
Statistical analysis. Unless otherwise stated, statistical significance was assessed by either one-way ANOVA 
or two-way ANOVA followed by Bonferroni’s post-test to compare combination treatment with single treatments 
and control using the GraphPad Prism software. The Fisher’s Exact test was used in the Oncomine Software anal-
ysis to determine statistical significance. The p-values determined by the R2 software were obtained by log-rank 
tests.
Statistical significances are depicted as *p < 0.05, **p < 0.01 and ***p < 0.001.
Ethical approval and consent to participate. Obtaining tumour specimens for culturing GB stem 
cell-like cells was approved by the Ethics Committee, Medical Faculty, Ulm University. All animal experiments 
were approved by the Regierungspräsidium Tübingen, Germany. All methods were performed in accordance with 
the relevant guidelines and regulations.
Results
Clinical relevance of targeting NFkB and gap junction in GB patients. Our previously published 
results strongly suggest that DIS and CBX affect NF-κB-mediated cell-substrate adhesions and gap junction-me-
diated cell-cell interactions in GB cells, respectively (for further support see Fig. S1 and Fig. S2)13,17. To strengthen 
further the validity of targeting NF-κB and gap junction in GB therapy, we hypothesized that a) GB cells should 
express higher levels of components of the NF-κB signalling machinery and gap junction-forming connexin 
proteins than healthy brain and b) there should be a correlation between NF-κB molecules and connexin on 
the one hand and tumour aggressiveness and reduced survival on the other. We, therefore, turned to publicly 
available databases (OncomineTM and R2, see Materials and Methods for details) and could verify that expres-
sion of NFKB1 (encoding the NF-κB p105 subunit), RELA (p65 subunit) and gap junction genes such as GJA4 
(gap junction alpha-4 protein, Connexin 37) and GJA10 (gap junction alpha-10 protein, Connexin 62) were 
significantly higher in GB (n = 542) than in healthy brain (n = 10) (Fig. 1a,b,e,f). In contrast, GJA1 (gap junction 
alpha-1 protein, Connexin 43), GJA3 (gap junction alpha-3 protein, Connexin 46) were similarly expressed in 
healthy and diseased brains (Fig. 1c,d). This is to be expected even though putative roles for Connexin 43 and 
46 in GB biology have previously been identified24,25. Connexin 43 also has a vital function in the healthy brain, 
such as mediating astrocyte survival26, while Connexin 46 so far has only been identified in GB stem TiCs which 
only contribute a minute fraction to the overall tumour bulk and, thus, is unlikely to appear upregulated in total 
GB24. However, both Connexin 43 and 46 are more highly expressed in GB than in neural stem cells (Fig. S3). 
Connexin 37 is mainly considered a vascular protein present in brain blood vessels27. It is tempting to speculate 
that its increased expression reflects increased vascularization within the tumour. Interestingly, there have been 
no reports linking Connexin 62 to tumour biology; it appears to be associated with connexin hemichannels of 
horizontal cell dendrites in the retina28.
Importantly, the high expression of NFKB1 and GJA1 correlated with reduced overall survival as well as with 
reduced progression-free survival when comparing 504 GB patient samples (Fig. 1g–j).
Determination of DIS and CBX concentrations for combinatorial treatment of undifferentiated 
and stem-cell like primary GB cells. To further elucidate the roles of cell-cell and cell-substrate inter-
actions in GB we selected the previously characterized, patient-derived G40 cells. G40 cells are negative for 
MGMT protein, i.e. considered resistant to TMZ-induced apoptosis, and highly invasive in an orthotopic mouse 
model21,22. Two distinct populations were created: the spheroid-forming G40-TiC and the adherently cultured 
G40-Dif. While these populations represent two distinct differentiated populations, they are also representative 
of different dominant forms of cellular interactions: The G40-TiC mainly form cell-cell interactions, while the 
G40-Dif adhere to ECM-substratum (Fig. 2a).
First, we determined the optimal concentration of DIS and CBX to be used for combinatorial treatment. 
G40-TiC and G40-Dif cells were treated for up to 96 hours with either DIS for the inhibition of focal adhesions 
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Figure 1. Expression of NF-κB and gap junction genes in GB and their impact on overall patient survival. 
Comparative gene expression [brain (1) vs. GB (2)] of NF-κB family member genes NFKB1 (p < 0.001) 
(a), RELA (p < 0.001) (b), Gap junction genes GJA1 (not significant) (c), GJA3 (not significant) (d), GJA4 
(p < 0.001) (e) and GJA10 (p < 0.05) (f) was visualized using Oncomine Software. Sample size: as indicated. 
High expression of NFKB1 (g) and GJA1 (i) is a negative prognostic factor for the overall survival in GB 
patients. GB patients with NFKB1 (h) and GJA1 (j) high expression also negatively affect disease-free survival. 
Kaplan-Meier curves were prepared by the R2 software in the scan cut-off mode. In addition to the raw 
p-values (raw p), the adjusted p-values after Bonferroni correction are given (bonf p), which require a stricter 
significance threshold.
www.nature.com/scientificreports/
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Figure 2. Effect of Disulfiram and Carbenoxolone on G40-TiC and G40-Dif GB cells. (a) Shown are primary 
tumour-initiating cells G40 (G40-TiC) cultured as free-floating clusters (left) and adherent differentiated GB 
cells (G40-Dif), which were derived from G40-TiC (right). (b) G40-TiC were either left untreated (exposed to 
DMSO solvent, vehicle) or treated with indicated concentrations of Disulfiram (DIS) and were counted every 
24 h for a total of 96 h using Cell counter Casy1. Untreated controls after 24 h were defined as 1. (c) G40-TiC 
cells were cultured either in the presence or absence (vehicle, exposed to DMSO) of DIS for the indicated 
time points. Percentage of DNA-fragmentation of propidium iodide-stained nuclei, a surrogate for apoptosis 
commitment, was determined by FACS analysis. (d) G40-TiCs were either treated with water (vehicle) or 
with indicated concentrations of Carbenoxolone (CBX). The cell number was measured at indicated times 
whereas untreated controls after 24 h were defined as 1. (e) CBX-induced DNA-fragmentation was measured 
by FACS analysis. (f) G40-Dif cells were seeded and treated with vehicle (DMSO control), 1, 5 and 10 µM DIS, 
followed by cell counting at indicated times, where cell numbers were normalized to control vehicle at 24 h. 
www.nature.com/scientificreports/
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or the gap junction inhibitor CBX. The slight reduction in G40-TiC cell number, only significant at 96 hours after 
treatment with 40 µM of DIS, is unlikely to be due to cell death, as no apoptosis could be observed (Fig. 2b,c). 
Indeed, the negative values in specific apoptosis are indicative for a potentially protective role of DIS, possibly due 
to the reduction in proliferation, which also can reduce spontaneous apoptosis. In contrast CBX induced a rapid 
decline in G40-TiC cell numbers and a significant commitment to apoptosis after 48 hours (Fig. 2d,e). G40-Dif 
cells responded to DIS treatment even at a concentration of 1 µM which was detected by a decrease in cell num-
ber and apoptosis commitment at a concentration of 10 µM as early as 48 hours post treatment (Fig. 2f,g). 1 µM 
DIS was sufficient to prevent the translocation of p65 from the cytosol to the nucleus even after stimulation with 
TNF-α, hence leading to an inhibition of NF-κB signalling (Fig. S1a). While the effect of CBX on G40-Dif cell 
numbers appears strong, less apoptosis is induced than in G40-TiC cells (Fig. 2h,i respectively). A concentration 
of 160 µM CBX was sufficient to inhibit gap junctions irreversibly (Fig. S1b). This concentration is well within 
the range of what is used experimentally as single dose treatment and which might be achieved in the patient by 
multiple smaller doses29,30. In contrast, Chekeni and co-workers, for example, used 500 µM CBX31.
Taken together these data show that suspension-grown G40-TiC cells are much more resistant to the effects 
of DIS than adherent G40-Dif cells, while both cells show sensitivity towards concentrations of CBX within the 
commonly used range.
Effect of combinatorial treatment of DIS and CBX on undifferentiated and stem-cell like primary 
GB cells on cell numbers, apoptosis and cell morphology. Based on experiments with the individual 
substances, as well as a titration analysis of CBX in combination with DIS (Fig. S4), the concentration of DIS and 
CBX for the combinatorial treatment was determined. The lowest concentration with a visible effect of the first 
effective substance, i.e. CBX for G40-TiC and DIS for G40-Dif, was combined with the second, ineffective drug 
of the other cell population. The purpose of this combination was to demonstrate that the combination is not 
antagonistic, i.e. the benefit of one substance that acts on the one subpopulation is not counteracted by the second 
substance. Therefore, G40-TiC and G40-Dif cells were treated with 40 µM DIS and 160 µM CBX or 1 µM DIS and 
160 µM CBX, respectively. Cell numbers declined and DNA fragmentation was increased 96 hours after treatment 
in cells treated with either the single substance (160 µM CBX for TiCs and 1 µM DIS for Difs) or in combination. 
This effect was not further enhanced in G40-TiC cells when treated in combination of DIS and CBX (Fig. 3a,b). 
However, a slight, but significant decrease in cell numbers and increase in apoptosis commitment was detectable 
in G40-Dif cells (Fig. 3c,d). Similarly, combining DIS and CBX with the commonly used chemotherapeutic TMZ 
did not block the efficacy of either inhibitor or DNA-damaging drug (Fig. 3e,f).
Impact of combined treatment of DIS and CBX on cell signalling molecules. Next, we investigated 
the effects of the two substances on cellular signalling pathways, with particular emphasis on the Raf/Mek/Erk 
and PI3K/Akt survival networks, which are dysregulated in various cancers. Furthermore, adherens junctions 
and ECM interactions are known activators of these pathways that are key mediators of adhesion-mediated apop-
tosis resistance (AMAR)11,17.
Analysis of survival factors in G40-TiC cells revealed a reduction in pAkt levels and an increase in caspase-3 
cleavage, 24 hours after DIS and combined treatment of DIS and CBX, whereas CBX reduced pSrc, which – inter-
estingly – did not occur upon combination treatment (Fig. S5a). As suggested by the data presented in Fig. 3, the 
combination of both substances had a larger effect on G40-Dif cells (Fig. S5). Here, individual substances had 
only a slight effect on the two pathways, but pAkt and pERK levels were significantly reduced upon combinatorial 
treatment of DIS and CBX. While low levels of cleaved caspase-3 were detectable after DIS treatment, DIS com-
bined with CBX induced a stronger activation of caspase-3 (Fig. S5b). This is in support of the previously shown 
data, suggesting that the combination treatment has a much stronger apoptotic effect in G40-Dif cells (Fig. 3d).
Investigating proteins involved in cell cycle progression and ultimately proliferation, we found a reduction in 
cell cycle kinases, such as Cdc2 and Cdk2, in G40-TiC and G40-Dif cells treated with DIS and CBX (Fig. S5c,d). 
Here, the individual substances had almost equal effects in G40-TiC and combining them did not appear to 
enhance this effect further (Fig. S5c). In contrast, combining both substances had a strong effect on G40-Dif cells, 
while the individual components only exhibited a negligible causatum (Fig. S5d).
In conclusion, while the combinatorial use of DIS and CBX was originally envisaged to target different cell 
populations within the tumour, and therefore the requirement for those two substances was merely not to antag-
onize each other, we found that the combination of DIS with CBX had a major inhibitory effect on survival and 
cell cycle proteins involved in proliferation and apoptosis (Fig. 3 and Fig. S5).
Effect of combinatorial treatment of DIS and CBX on G40-Dif and G40-TiC cell morphology and 
adhesion. A major obstacle in successfully treating GB is the highly infiltrative nature of the malignancy, 
which makes localized excision practically impossible7. Furthermore, invasive cells are frequently associated with 
(g) Percentage of specific apoptosis was determined by FACS analysis after 24 h, 48 h, 72 h and 96 h treatment 
with indicated concentrations of DIS. (h) G40-Dif cells were either left untreated (exposed to water, vehicle) 
or treated with 40, 80 and 160 µM CBX. Cell number was determined at indicated time points. (i) Specific 
apoptosis was measured by FACS analysis of DNA fragmentation of propidium iodide-stained nuclei after 
24 h, 48 h, 72 h and 96 h. (a) Scale bar: 50 µm. (b)–(i) Mean and SEM of three replicates of three independent 
experiments are shown. Statistical significance was determined by Two-way ANOVA followed by Bonferroni’s 
post-test (*p < 0.05, **p < 0.01, ***p < 0.001). DNA fragmentation [%] was calculated as: 100 × (experimental 
apoptosis (%) - spontaneous (vehicle) apoptosis (%))/(100%-spontaneous (vehicle) apoptosis (%)).
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Figure 3. Combinatorial treatment of DIS and CBX reduces cell growth and induces apoptosis of GB cells. (a) 
G40-TiCs were seeded and immediately treated with indicated concentrations of DIS and CBX for 96 hours. A 
change in cell numbers was determined by the use of Casy1 cell counter, whereas the cell number of untreated 
cells (DMSO and H2Obid, vehicle) after 24 h was defined as 1. (b) G40-TiCs were treated for 96 h with DIS, 
CBX or both as indicated. Staining for propidium iodide was performed prior to flow cytometric analysis. (c) 
G40-Dif cells were cultured either in the presence or absence of DIS and CBX for 96 h, before cell number was 
measured. Untreated controls after 24 h were defined as 1. (d) G40-Dif cells were seeded and subsequently 
treated with indicated concentrations of DIS and CBX or control vehicle (DMSO and H2Obid). Percentage of 
DNA-fragmentation of propidium iodide-stained nuclei was visualized via flow cytometry. (e) GB cells, either 
G40-TiC or G40-Dif were either treated with vehicle, the combination of DIS and CBX used in (a)-(d), 100 µM 
TMZ or a combination of all three substances. A change in cell numbers was determined after 144 h by the 
use of Casy1 cell counter. (f) GB cells, G40-TiC or G40-Dif were either treated with vehicle, the combination 
of DIS and CBX used in (a)-(d), 100 µM TMZ or a combination of all three substances. Percentage of DNA-
www.nature.com/scientificreports/
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structures that mediate increased apoptosis resistance10. Therefore, we next investigated the potential of the two 
substances in preventing the interaction between the tumour cells and their environment.
Cell-substrate contact-forming (i.e. adherent) G40-Dif cells were examined after DIS and CBX treatment by 
time-lapse analysis with regards to cell morphology, spreading and adhesion. Whereas CBX treatment on its own 
did not have an impact on cell morphology or adhesion, 1 µM DIS was sufficient to detach the cells approximately 
40 hours post treatment. By 48 hours non-adherent cell clusters have clearly formed (Fig. 4, supplementary video 
files). In contrast, as early as 1 hour after treatment of the cells with the combination of DIS and CBX, G40-Dif 
cells lost their ability to attach to the plastic and the length of the pseudofilopodia decreased in comparison to 
the control. Within 3–6 hours cells appeared fully detached (Fig. 4, supplementary video files). Importantly, in 
contrast to single treatment with DIS, the addition of CBX prevented cluster formation. Similar results were also 
obtained, when allowing stem cell-like cells to adhere in differentiation medium. Here 40 µM DIS prevented 
adhesion and thus differentiation, while the combination of DIS and CBX prevented adhesion and sphere forma-
tion (Fig. S6).
Establishing and characterizing an adherent tumour-initiating cell model to monitor cell invasion. 
Next, we asked whether the different sensitivity of G40-TiC versus G40-Dif towards DIS is due to the different 
dominant adhesion forms, i.e. Dif cells are more sensitive as they are dependent on cell-ECM interactions, or 
whether the divergent differentiation status also contributes to this phenotype. To overcome this problem, we 
established an adherent G40-TiC cell model based on pre-existing protocols32, which also allowed us to investi-
gate the locomotive potential of these stem cell-like cells. Collagen I, a compound of the ECM, is highly elevated 
in GB and contributes to tumour progression33. Hence collagen type I coated culture flasks were chosen for 
further investigations of the invasive phenotype of G40-TiC cells as it did not affect overall signalling of the cells 
(Fig. S7).
Adherent G40-TiC cells did not display increased sensitivity towards low concentrations of DIS (1 µM), sug-
gesting that DIS sensitivity is not a mere consequence of adhesion (Fig. 5a,b,d). Interestingly, these cells did 
become more sensitive towards high concentrations of DIS (40 µM), CBX and the combination of both drugs 
(Fig. 5a,b; for complete statistical analysis see Supplementary Table S1).
Next, cell motility of adherent G40-TiC cells, G40-Difs and G40-TiCs was monitored via time-lapse micros-
copy. G40-TiCs on collagen type I coated culture flasks migrated significantly faster than G40-Dif cells, although 
when cultured on collagen, G40-Dif cell velocity was similar to that of G40-TiC cells on collagen, indicating that 
collagen had an impact on the motile phenotype (Fig. 5c). Furthermore, cell velocity upon DIS, CBX and com-
bined treatment was analysed. None or only slight effects on cell velocity were detectable in 1 µM DIS or CBX 
treated G40-TiC cells (Fig. 5d). However, 1 µM DIS and 160 µM CBX combined slowed down cell movement 
significantly after 48 hours, whereas no migration of G40-TiC cells on collagen was detected when treated with 
40 µM DIS alone or in combination with CBX. Importantly, similar to CBX, high concentrations of DIS and the 
combination also affect the apoptosis commitment of the adherent G40-TiCs (Fig. 5b), the possibility cannot 
be fully excluded that it is not the machinery of motility that is directly affected, but the general viability of the 
cells. However, there is no clear correlation between increase in apoptosis commitment and decrease in velocity 
(compare Fig. 5b with d).
On the other hand, CBX treatment on its own had no impact on G40-Dif cell migration, whereas 1 µM DIS 
and the combination of DIS and CBX was sufficient to detach cells at 24 hours and therefore ablated the invasive 
phenotype completely (Fig. 5e). Notably, the effect of DIS and CBX in G40-Dif cells was independent of the cul-
ture conditions (Fig. S8).
Taken together these data indicate that, while stem cell-like GB cells are more resistant to the effects of DIS, 
combining this substance with CBX, particularly at high concentrations, sensitizes these cells for cell death and 
reduces total numbers of tumour cells. Importantly, DIS and CBX combined have an anti-invasive effect on both 
cell populations investigated.
Validating the DIS and CBX combination approach. To verify that the observed effects of DIS and 
CBX are not specific for G40 cells, but represent a more general feature of GB cells, we investigated the effects 
of these substances on two additional pairs of highly invasive, TMZ-resistant patient-derived cell populations, 
G35 and G3821,22 (Fig. 6a–d). As with the G40 cells we observed that G35-TiC and G38-TiCs are less sensitive 
towards DIS-induced apoptosis than G35 and G38-Dif cells (Fig. 6b–d). However, both additional TiC popu-
lations reacted less strongly towards CBX-induced apoptosis than G40-TiCs, CBX still reduced total cell num-
bers of G35-TiC and G38-TiC by approximately 30% (Fig. S9). Importantly, combining both substances also 
did not reduce the effect of the individual substances, thus confirming no adverse drug-drug interactions upon 
anti-tumour efficacy.
Next, we investigated the effects of DIS and CBX in an in vivo setting. G40 cells are highly lethal in an ortho-
topic mouse model as they do not form a solid tumour13,21. We therefore selected the G35-TiC cells and implanted 
them into mouse brains. 7 days after implantation, mice were treated interperitoneally with DIS, INI-0602 – a 
variant of CBX optimized to cross the blood-brain barrier, but with otherwise similar chemical properties29, 
fragmentation of propidium iodide-stained nuclei was visualized after 144 h via flow cytometry. Mean and SEM 
of three independently conducted experiments in triplicate are depicted. Statistical significance was determined 
by One-way ANOVA followed by Bonferroni’s multiple comparison test (*p < 0.05, **p < 0.01, ***p < 0.001, 
ns: not significant (p > 0.05)). DNA fragmentation [%] was calculated as: 100× (experimental apoptosis (%) - 
spontaneous (vehicle) apoptosis (%))/(100%-spontaneous (vehicle) apoptosis (%)).
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TMZ or a combination of all three substances. After sacrificing the animals 11 days post operation (4 days post 
treatment) tumour formation was analysed (Fig. 6e). As expected from previous data, DIS had a strong antitumor 
effect on the GB tumour bulk13, while surprisingly tumours treated with CBX appeared larger. It is tempting to 
speculate that this is due to the cells being less densely packed within the bulk, as treatment with CBX alone had 
no discernible effect on overall survival (Fig. S10). Importantly, no tumour bulk was detectable upon triple treat-
ment with DIS, CBX and TMZ (Fig. 6e).
From previous experience (data not shown), it is to be deduced that when treatment was given at Day 7, GB 
cells were already invasive. In addition, untreated mice already began dying at Day 17 (Fig. S10). Accordingly, 
invasive cells were found in all brain sections analysed independently of treatment. However, the morphology of 
invasive cells exposed to triple treatment was noticeably different, and cells appeared considerably smaller and 
rounded, indicating reduced locomotive capacity and/or viability.
Taken together, these data strongly suggest that the addition of DIS and CBX to the standard therapeutic 
approach for GB treatment might have a beneficial effect, affecting both the size of the tumour bulk and the inva-
sive potential of individual cells.
Figure 4. Effect of combination treatment with DIS and CBX on G40-Dif cell morphology, spreading and 
adhesion. G40-Dif cells were treated with indicated concentrations of DIS and CBX and pictures were taken 
at 10 min intervals over a time frame of 48 hours. Shown in (a) are representative images of two independent 
experiments of selected time points (0, 4, 32, 48 h). Scale bar: 200 µm. (b) Quantitative analysis of the cells 
shown in (a). The percentage of cells that were not spread at 0, 1, 2, 4, 8, 16, 32 and 48 h after treatment was 
calculated by counting all cells and dividing the non-spread cells by the total number of cells visible. Detailed 
video files have been deposited online as supplementary data.
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Figure 5. The effects of DIS and CBX on adherent G40-TiC cells and contrasting G40-TiC versus G40-Dif 
motility. (a) Effect of collagen type I on cell numbers. G40-TiCs grown on collagen were seeded and treated with 
DIS and CBX. A change in cell numbers was determined at the four indicated time points by the use of Casy1 cell 
counter. Untreated controls (vehicle) after 24 h were defined as 1. (b) Specific apoptosis in DIS- and CBX-treated 
G40-TiCs grown on collagen. G40-TiCs cultured on collagen type I were seeded and immediately treated with 
1 µM DIS, 40 µM DIS, 160 µM CBX or a combination of both. This was followed by FACS analysis of the DNA 
fragmentation of propidium iodide-stained nuclei. (c) Cell velocity of G40-Dif cells cultured in the presence 
or absence of collagen and G40-TiCs grown on collagen was recorded every 20 minutes for 60 h via time-lapse 
microscopy. Migratory activity was analysed with ImageJ software (n = 80). (d) Cell movement of G40-TiCs 
cultured on collagen was examined in four 8-hour intervals (24–56 hours after seeding and immediate treatment 
with DIS and CBX) and analysed with ImageJ software (n = 20). (e) Cell velocity of G40-Dif cells was examined 
in four 8-hour intervals (24–56 h after seeding and immediate treatment with DIS and CBX) and analysed with 
ImageJ software (n = 20). Mean and SEM are depicted of three independently conducted experiments in triplicate. 
Statistical significance was determined by ANOVA followed by Bonferroni’s post-test (*p < 0.05, **p < 0.01, 
***p < 0.001, ns: not significant (p > 0.05)). DNA fragmentation [%] was calculated as: 100× (experimental 
apoptosis (%) - spontaneous (vehicle) apoptosis (%))/(100%-spontaneous (vehicle) apoptosis (%)).
www.nature.com/scientificreports/
1 1SCIENtIFIC REPORTs |  (2018) 8:5527  | DOI:10.1038/s41598-018-23592-z
Discussion
Due to its unfocused growth and highly invasive nature, therapeutic options for GB are severely limited. Localized 
treatment, such as surgical resection and radiotherapy, might successfully eliminate the tumour bulk, but are 
unlikely to affect the tumour cells dispersed throughout the brain, leading to rapid recurrence4. The application 
of systemic chemotherapy, however, is highly limited due to the blood-brain-barrier. The only chemotherapeutic 
routinely given to GB patients, TMZ, only prolongs patient’s life expectancy by a few months34. This sobering fact 
might be due to several reasons, not least the association of invading GB cells with brain structures that increase 
apoptosis resistance9,10. Clearly, new conceptual approaches to GB therapy are needed.
Taking our cue from the famous prison island of Alcatraz, which put several (overlapping) isolating circles 
between the prisoners and society, we postulate the Alcatraz Strategy: Isolating GB from their direct microenvi-
ronment within the brain, and, thus, reducing invasion and turning GB into a more focused disease that is less 
therapy resistant.
Figure 6. The effects of DIS and CBX on additional GB cell populations and their therapeutic potential 
evaluated in vivo TiCs (a,b) or Difs (c,d) derived from two additional patients, G35 and G38, were treated with 
concentrations of DIS, CBX or a combination thereof, similarly to those used with G40 cells for 96 h. (b–d) 
Staining for propidium iodide was performed prior to flow cytometric analysis. Mean and SEM are depicted of 
three independently conducted experiments in triplicate. Statistical significance was determined by One-way 
ANOVA followed by Bonferroni’s post-test (*p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant (p > 0.05)). 
DNA fragmentation [%] was calculated as: 100× (experimental apoptosis (%) - spontaneous (vehicle) apoptosis 
(%))/(100%-spontaneous (vehicle) apoptosis (%)). (e) Mouse brain sections of similar depth, showing the 
maximal tumour bulk. Twelve mice (at least two per treatment group) were injected orthotopically with human 
G35-TiC cells (visualized red by Vimentin), left untreated or 7 days post injection treated with indicated 
substances or combinations thereof. Mice were sacrificed 11 days post injection. Concentrations were selected 
according to previously described literature: DIS13, CBX/ INI-060229 and TMZ22. Importantly, the chosen TMZ 
concentration alone previously did not prevent GB-associated death in an identical experimental system22. 
(a),(c) scale bar: 50 µm. (e) scale bar: 1000 µm.
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Here, we selected two of those interactions, cell-substrate adhesion and gap junctions and using genet-
ically identical cell populations, which – due to their alternative differentiation statuses – expressed different 
forms of dominant cellular interactions to test our hypothesis. Blocking gap junctions, which are found in 
suspension-cultured tumour-initiating cells (TiCs) and – although of a more transient nature – in differentiated 
cells (Difs), affected apoptosis and total cell numbers in both cell populations. In contrast, blocking cell-substrate 
interaction only affected the Dif population. Even concentrations of the inhibitor Disulfiram (DIS) far exceeded 
the physiologically relevant doses, had only minor effects on the TiC cell clusters. The latter is to be expected, as 
under the given culture conditions these cells do not adhere to substrate. However, under induced adherence 
(which did not lead to differentiation) these cells remained resistant to DIS treatment – suggesting that adhesion 
in TiCs is somehow fundamentally different from adhesion in Difs. This is in line with our recent data, suggesting 
that motility, i.e. dynamic adhesion turnover, is differently regulated in those two cell populations and opens 
interesting avenues for further research. Investigating how TiCs migrate and cataloguing potential inhibitors 
will enhance our general knowledge of GB biology and identify additional components of the Alcatraz Strategy.
Importantly, combining the cell-substrate inhibitor DIS and the gap junction blocker Carbenoxolone (CBX), 
either with only each other or additionally with TMZ, does not inhibit the efficacy of the individual substances, 
i.e. they are suitable candidates for a complex combination therapy that adds to the current standard treatment.
Possibly the most striking feature of our investigation is the emergence of cooperation between DIS and CBX, 
where therapeutically beneficial alterations occur which are not the mere sum of the effects exerted by the individual 
compounds, and when blocking Dif motility. While DIS alone can effectively lead to loss of adhesion, this only occurs 
40 hours after treatment initiation. As clearly visible in the time-lapse data provided online, prior to detachment, cells 
undergo a morphological change – increasing the surface area in contact with neighbouring cells. We speculated that 
this is an attempt to change the dominant form of adhesion from cell-substrate to cell-cell interaction, a phenomenon 
we described earlier17. The addition of CBX further altered the kinetics, leading to a detachment within 3 hours. Here 
we clearly see that the two substances we selected to affect different cell populations also strongly synergize.
An independent line of reasoning supports our notion that NF-κB and gap junctions, the direct targets of the 
inhibitors, are crucial for GB, which was established by mining publicly available data sets. Here, we could show 
that our molecules of interest are more highly expressed in GB compared to healthy brain and expression is asso-
ciated with poorer diagnosis in patients, further validating our target selection.
Blocking cellular interactions as a therapeutic avenue is often viewed with scepticism for fears that this might 
facilitate epithelial-to-mesenchymal transition (EMT), creating a more motile phenotype of cancer cells and thus 
actually enhancing invasion and metastasis. Although GB cells do not undergo classical EMT, no basement mem-
brane is present and E-cadherin is only rarely expressed in GB35. The gene expression profile of human mammary 
epithelial cells that have undergone EMT is similar to that of GB cells36, i.e. GB cells are already highly motile and 
targeting interaction points with the microenvironment is unlikely to enhance this effect further. Nevertheless, we 
have selected cellular interactions which are not considered to be adhesions per se. Furthermore, for cell-substrate 
interactions we have not selected a specific inhibitor, such as the integrin inhibitor Cilengitide which has not lived 
up to its initial therapeutic promise12. Instead we selected DIS, an off-patent drug that has been used in the treat-
ment of chronic alcoholism by inhibition of acetaldehyde dehydrogenase (ALDH). It is known to be well tolerated 
with low toxicity and only minor side effects37. DIS has been shown to exert therapeutic benefits on GB cells 
via different mechanisms, such as blocking NF-κB, proteasome inhibition and a reduction of DNA repair path-
ways13,38–40. In turn, we utilized the DIS-inhibition of NF-κB to block cell-substrate contacts and, thus, invasion13, 
which also has additional therapeutic benefits, such as antiproliferative effects40,41. This could explain why, in our 
mouse model, we see a reduction in tumour bulk as well as reduced invasion. Importantly, this putative reduction 
in proliferation does not interfere with TMZ-induced cell death. This is in line with other data showing that sen-
sitivity towards this chemotherapeutic treatment does not correlate with proliferation rates42. DIS is already being 
clinically evaluated as one of nine repurposed drugs (CUSP9) in the novel treatment approach against GB43, while 
a phase I trial recently revealed that DIS can be safely combined with TMZ in the treatment of GB patients44.
CBX, which is structurally related to the chief constituent of liquorice roots, is being used to treat gastric ulcers and 
other types of inflammation45. While we used CBX as a water-soluble inhibitor of gap junctions, it is relatively nonspe-
cific also blocking other potential routes of cellular signalling, such as NMDA receptors, GABAA receptors, and calcium 
channels45. Importantly, it is not a general inhibitor of connexins. While being the main proteins that make up gap junc-
tions, connexins also have intracellular signalling functions that have been described as tumour-suppressive, e.g. acting 
as an inhibitor of cell growth46. Therefore, targeting the structure of gap junctions is preferential to targeting connexins.
CBX has also been reported to reduce seizures, act in a neuroprotective manner and improve cognitive func-
tions45,47,48. These effects, not all related to its function as gap junction blocker, might have a beneficial effect on 
the overall well-being of GB patients.
Conclusion
Taken together, DIS and CBX are an ideal addition to a complex combination therapy that aims to isolate GB 
from its direct environment. These substances have a long history of clinical use and the side effects are therefore 
well-understood, the most severe being alcohol intolerance (due to DIS) and hypertension (due to CBX). The latter 
can be countered by co-administration of amiloride48. However, further additions to the Alcatraz Strategy still need 
to be considered, as tumour cells are well-known to be able to alternate between the different forms of interactions 
upon stress or microenvironmental changes11. Crucially, this is also reflected by different forms of motility these cells 
can adopt, particularly under selective pressure49,50. Monitoring the long-term effect of DIS and CBX on GB cells is 
therefore necessary to identify potential alterations in the underlying molecular mechanisms of invasion that arise due 
to selective pressure, and warrant the augmentation of further contact-inhibiting drugs. Nevertheless, it seems clear 
that adding DIS and CBX to the standard treatment for GB has the potential to improve the therapeutic window, both 
temporally and spatially, suggesting that further clinical evaluation should commence as soon as possible.
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